X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
(NASDAQ: XFOR) Delayed: 4.00 +0.12 (3.09%)
Previous Close $3.88    52 Week High $ 
Open $3.93    52 Week Low $ 
Day High $4.02    P/E N/A 
Day Low $3.90    EPS $ 
Volume 501,533